A multi-center, randomized, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of 200, 400, and 600 mg/day SPM 927 [lacosamide] in subjects with painful distal diabetic neuropathy

Trial Profile

A multi-center, randomized, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of 200, 400, and 600 mg/day SPM 927 [lacosamide] in subjects with painful distal diabetic neuropathy

Completed
Phase of Trial: Phase II/III

Latest Information Update: 25 Apr 2015

At a glance

  • Drugs Lacosamide (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 25 Apr 2015 Results of pooled and subgroup analysis presented at the 67th Annual Meeting of the American Academy of Neurology.
    • 15 Sep 2009 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
    • 01 Jun 2009 Primary endpoint average daily pain score (on an 11-point Likert pain scale) has been met according to results published in the Clinical Journal of Pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top